Editorial Board ::: Current Cancer Therapy Reviews

ISSN: 1875-6301 (Online)
ISSN: 1573-3947 (Print)


Volume 13, 2 Issues, 2017


Download PDF Flyer




Current Cancer Therapy Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Kurt S. Zaenker
Institute of Immunology and Experimental Oncology University Witten/Herdecke
Stockumerstraße 10, 58448 Witten
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Editorial Board

Editor-in-Chief:

Kurt S. Zaenker
Institute of Immunology and Experimental Oncology University Witten/Herdecke
Stockumerstraße 10, 58448 Witten
Germany



Associate Editor:

Franco M. Muggia
New York University Medical Center
New York, NY
USA


Regional Editors:

Region: Europe
D. Santini
Department of Medical Oncology University Campus Bio-Medico
Rome
Italy
Region: Norrth America
K. Camphausen
Radiation Oncology Department
National Institute of Health
Bethesda, MD
USA

Editorial Board Members:

R.J. Ablin
University of Arizona College of Medicine
Arizona
USA

D. Assimakopoulos
Univ. Ioannina Sch. Med.
Ioannina
Greece

E.E. Baulieu
INSERM U488
Le Kremlin Bicetre
France

J.R. Bertino
UMDNJ-Robert Wood Johnson Med. Sch
New Brunswick, NJ
USA

B. Bonavida
UCLA School of Medicine
Los Angeles, CA
USA

D.J. Buchsbaum
Univ. of Alabama at Birmingham
Birmingham, AL
USA

G. Carruba
ARNAS-Civico
Palermo
Italy

P. Chandra
Klinikum der Universitat
Frankfurt
Germany

F. Ciardiello
Second University of Naples
Naples
Italy

V.P Collins
Addenbrooke's Hospital
Cambridge
UK

W.S Dalton
Univ. S Florida H Lee Moffitt Canc. Ctr.
Tampa, FL
USA

S.J. Day
John Wayne Canc. Inst
Santa Monica, CA
USA

M Detmar
Massachusetts Gen. Hosp
Boston, MA
USA

P.B Fisher
Columbia University Coll. Phys. & Surg.
New York, NY
USA

H.S. Friedman (Biography
H.S. Friedman

Dr. Henry S. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings. He is the senior editor of CNS Oncology, was the Associate Editor for the Neuro-Oncology Section of Cancer for 15 years and is a reviewer for over 25 academic journals.

)

Duke Univ. Med. Ctr.
Durham, NC
USA

Mario D. Galigniana (Biography
Mario D. Galigniana

We study the biological role of two Hsp90-binding immunophilins, FKBP51 and FKBP52. We have postulated a novel model for the mechanism of action of steroid receptors, where FKBP52 links the receptor-Hsp90 complex to motor proteins favouring receptor retrotransport on cytoskeletal tracts, its passage through the nuclear pore and transcriptional activation. FKBP51 antagonizes these effects. The model was extended to other factors (HSF1, p53, NF-kB) and proposes that the FKBP52/FKBP51 expression ratio regulates the final biological response of factors with pleiotropic action. We have also demonstrated that both immunophilins regulate neurodifferentiation, and have identified FKBP51 as a novel mitochondrial factor. It shows antiapoptotic action, is overexpressed in tumor cells and enhances telomerase activity.

)

University of Buenos Aires
Buenos Aires
Argentina

G Gasparini
Azienda Complesso Ospedaliero San Filippo Neri
Rome
Italy

S.L Gerson
Case Western Reserve Univ.
Cleveland, OH
USA

R Giavazzi
Mario Negri Inst. Pharmacol Res.
Bergamo
Italy

A.K Godwin
Fox Chase Canc. Ctr.
Philadelphia, PA
USA

J.W Gratama
Erasmus Cancer Center
Rotterdam
The Netherlands)

K Haustermans
University Hospital Gasthuisberg
Leuven
Belgium

I Hellstrom
University of Washington
Seattle, WA
USA

D Ilson (Biography
D Ilson

Dr. Ilson is attending physician and member at Memorial Hospital, and professor of medicine at Weill-Cornell Medical College. His research interest is upper gastrointestinal cancer with a focus on esophageal cancer. His research focuses on the study of new agents in advanced esophageal cancer and in combined modality therapy. He sits on U.S. NCCN Gastric Cancer guideline panel, and the GI Cancer committees of Alliance/CALGB and NRG/RTOG. He is the former chair of the U.S. NCI Esophageal and Gastric Cancers Clinical Trial Task Force.

)

Memorial Sloan-Kettering Cancer Center
New York, NY
USA

Y Ito
Kuma Hospital
Kobe
Japan

F.F Kadlubar
University of Arkansas
Little Rock, AR
USA

L Kelland
St. George Hosp. Sch. Med. Antisoma Res. Lab
London
UK

R Kurzrock
Univ. Texas MD. Anderson Canc. Ctr.
Houston, TX
USA

E Lundgren
Umea University
Umea
Sweden

F.M Marincola
Clinical Center, NIH
Bethesda, MD
USA

C.J Melief
Leiden University
Leiden
The Netherlands

S Merajver
Univ. Michigan Sch. Med.
Ann Arbor, MI
USA

H Mukhtar
Univ. Wisconsin
Madison, WI
USA

R Narayanan (Biography
R Narayanan

Ramaswamy Narayanan earned his Ph.D. in biochemistry in 1980 from the National University of Dublin, Ireland. He has worked at the NCI, CDC, the Yale University, Memorial Sloan Kettering Cancer Center, and at the Hoffmann-La Roche, Inc. He has published over 140 peer-reviewed publications and numerous book chapters. He is a Professor at Florida Atlantic University for the last seventeen years, where his work has led to two issued patents and the first Biotech spin-off company for the University. His research revolves around the genomics of cancer and other diseases.

)

Florida Atlantic University
Boca Raton, FL
USA

G.L Nicolson (Biography
G.L Nicolson

Garth L. Nicolson, Ph.D., M.D. (H) is the President, Chief Scientific Officer and Professor Emeritus at the Institute for Molecular Medicine in Huntington Beach, California. Having published over 675 medical and scientific papers, including editing 20 books, he has served on the Editorial Boards of 30 medical and scientific journals. He has won many awards, including the Burroughs Wellcome Medal, Royal Society of Medicine (London), Stephen Paget Award, Metastasis Research Society, US National Cancer Institute Outstanding Investigator Award, and the Innovative Medicine Award (Canada). He is a Colonel (Honorary) of the US Army Special Forces and US Navy SEAL (Honorary) for Armed Forces and veterans’ illnesses.

)

The Institute for Molecular Medicine
Huntington Beach, CA
USA

R.F Ozols
Fox Chase Cancer Center
Philadelphia, PA
USA

N Pearce
Massey University
Wellington
New Zealand

C. Petrovas (Biography
C. Petrovas

My major scientific objective is to understand the cellular and molecular mechanisms of the development of “effective” immune responses as well as the manipulation of these responses, to develop novel immunotherapies. During my thesis (School of Medicine, National University of Athens, Greece) I studied the development of antibodies against major auto-antigens and the function of anti-phospholipid antibodies in autoimmunity and HIV infection. Currently, I am the head of the Tissue Analysis Core at VRC and our research focuses in the characterization of the dynamics of tissue immune cells in HIV/SIV and cancer and developing tools to understand the interplay between inflammation, adaptive immunity and tissue antigens.

)

Vaccine Research Center, NIAID, NIH
Bethesda, MA
USA

J.J Rafter
Karolinska Institutet
Huddinge
Sweden

A Ravaud
Hôpital Saint Andre
Bordeaux
France

R Rees
Nottingham Trent University
Nottingham
UK

A.K Shamsuddin (Biography
A.K Shamsuddin

Dr. AbulKalam M. Shamsuddin is Professor of Pathology at the University of Maryland School of Medicine in Baltimore. He received his medical degree from Dhaka University, and PhD from University of Maryland. He is the pioneering scientist to demonstrate the anti-cancer and immune enhancing function of inositol and inositol hexaphosphate (www.ip-6.net).

Dr. Shamsuddin has published several books, many book-chapters and numerous scientific papers. He serves in the Editorial Board of several cancer related journals; and is a highly sought after speaker in international scientific meetings.

)

Univ. Maryland Sch. Med.
Baltimore, MD
USA

D.A. Spandidos
Univ. Crete Sch. Med.
Crete
Greece

G.S. Stein
Univ. Massachusetts Sch. Med.
Worcester, MA
USA

S. Stylli (Biography
S. Stylli

Dr Stanley Stylli is a cancer research scientist at the Department of Neurosurgery, The Royal Melbourne Hospital and an Honorary Fellow of the Department of Surgery (RMH) at The University of Melbourne, Australia. He received his Master of Science and PhD degrees from The University of Melbourne. His research interests include glioma biology, invasion and identifying novel therapeutic targets for glioma. Currently he is investigating the influence of invadopodia in glioma invasion, the response of invadopodia to various therapeutic approaches and the role of tumour-derived exosomes (TEX) for invadopodia biogenesis in glioma.

)

The University of Melbourne
Melbourne
Australia

M.M Taketo
Kyoto University Grad. Sch. Med
Kyoto
Japan

K.D Tew (Biography
K.D Tew

Dr. Tew received his undergraduate degree from the University of Wales and graduate training at the University of London, where he received his Ph.D., and later a Doctor of Science in recognition of his accomplishments in cancer research.

Currently, Dr.Tew is the John C. West Chair in Cancer Research and the Chairman of the Department of Pharmacology at the Medical University of South Carolina. He has appointments to a wide variety of peer-review committees, editorial boards, and academic and industry scientific advisory boards, is a Fellow of the American Association for the Advancement of Science (AAAS).

)

Medical University of South Carolina
Charleston, SC
USA

P. Vaupel
University of Mainz
Mainz
Germany

D.K Watson
Med. University S Carolina Hollings Canc. Ctr.
Charleston, SC
USA

T. Whiteside (Biography
T. Whiteside

Dr. Theresa Whiteside is a Professor of Pathology, Otolaryngology and Immunology at the University of Pittsburgh and member of the University of Pittsburgh Cancer Institute. She is a recognized expert in immune monitoring of patients with cancer and has authored over 575 peer-reviewed publications and 127 chapters as well as a book on human tumor-infiltrating lymphocytes, also co-editing several scientific books. She has trained 94 post-doctoral fellows from the United States and abroad.

Her research interests include tumor immunology and immunotherapy. Currently, she is investigating the role of regulatory T cells in cancer progression as well as contributions of tumor-derived exosomes (TEX) to dysfunction of CD8+ effector cells in the peripheral circulation of patients with cancer and in the tumor microenvironment

)

Univ. Pittsburgh Sch. Med
Pittsburgh, PA
USA

G. XU (Biography
G. XU

Prof. Guoxiong Xu (MD, PhD) is a Scientist and Director of Center Laboratory in Jinshan Hospital, Fudan University, Shanghai, China. He obtained his PhD degree in Biology from York University in Canada. Dr. Xu is a molecular and cell biologist and has a proven track record on the molecular biology of cancer. He has presented his work in many national and international scientific conferences. His research works are supported by grants from the National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Science and Technology Commission of Shanghai Municipality, and Shanghai Municipal Commission of Health and Family Planning.

)

Fudan University
Shanghai
China

J.R Yannelli
Univ. Kentucky Sch. Med.
Lexington, KY
USA

A.A. Adjei
Mayo Clinic
Rochester, MN
USA

F. Balkwill
Barts & London Queen Mary's Sch. Med.& Dent
London
UK

J. Bergh
Karolinska Hosp. & Inst. Radiumhemmet
Stockholm
Sweden

M.V. Blagosklonny
New York Medical College
Hawthorne, NY
USA

E. Bouffet (Biography
E. Bouffet

Dr. Eric Bouffet is Professor of Paediatrics in the University of Toronto, Garron Family Chair in Childhood Cancer Research, Associate Senoior Scientist at the Research Institute, and Head of the Neuro-oncology Section in the Division of Haematology/Oncology at The Hospital for Sick Children, Toronto. His research interests are in the area of novel treatments and clinical trials in children with brain tumours. He is author or co-author of over 380 peer-reviewed manuscripts and author/co-author on numerous book chapters in the field of neuro-oncology.. In 2016, he became the President of the International Society of Paediatric Oncology (SIOP).

)

Hosp. Sick Children
Toronto, ON
Canada

R.M. Bukowski
Cleveland Clinic Taussig Canc. Ctr
Cleveland, OH
USA

W. Carson
Ohio State University
Columbus, OH
USA

E. Choy (Biography
E. Choy

Dr. Choy is the Director of Sarcoma Research at the Division of Hematology Oncology at MGH and Assistant Professor in Medicine at Harvard Medical School. He specialized in the medical management of patients with sarcomas, gastrointestinal stromal tumors, chordomas, and desmoid tumors. He works closely with a team of world class surgical, orthopedic, and radiation oncologists as well as connective tissue pathologists and radiologists to provide optimal care for his patients. He directs a clinical trials program at the MGH Center for Sarcoma and Connective Tissue Oncology that includes 9-12 active phase I-III clinical trials.

)

Harvard Medical School
Boston, MA
USA

R. Clarke (Biography
R. Clarke

Robert Clarke, Ph.D., D.Sc. leads Georgetown University Medical Center’s high performance research community, expanding its extramural funding and promoting the efforts of its faculty. Also, he works in collaboration with the Georgetown University Graduate School of Arts and Sciences to cultivate and strengthen the research components of the University’s graduate programs and the quality of graduate biomedical education. Clarke is co-director of the Georgetown-Lombardi Comprehensive Cancer Center breast cancer program, a professor in the Department of Oncology, and an internationally known breast cancer researcher.

)

Georgetown Univ. Sch. Med.
Washington, DC
USA

K.A Cooney
Univ. Michigan Med. Sch.
Ann Arbor, MI
USA

J.M Daly
Temple University Sch. Med
Philadelphia, PA
USA

J.F. Deeken (Biography
J.F. Deeken

Dr. Deeken is a medical oncologist and Associate Professor. He serves as COO of the Inova Translational Medicine Institute. His clinical research focus is the treatment of head and neck cancer. His areas of translational research include the use of genomics to personalize therapy, and to better understand the growing epidemic of H&N cancer caused by HPV. He completed his fellowship in Medical Oncology at the National Cancer Institute in 2006. He was director of the H&N Medical Oncology clinic at Georgetown University for a decade, where he an independent research laboratory and a member of its Phase I Clinic.

)

Inova Translational Medicine Institute
Falls Church, VA
US

L Dubeau
USC Keck Sch. Med
Los Angeles, CA
USA

R.J Fitzgibbons
Creighton University Medical Center
Omaha, NE
USA

S. Fuqua (Biography
S. Fuqua

Dr. Suzanne Fuqua received her Bachelor and Master of Science degrees from the University of Houston, and her PhD in Cancer Biology from the MD Anderson Cancer Center in Houston, Texas. She joined the the University of Texas Health Science Center at San Antonio as a postdoctoral fellow in 1985, attaining the position of tenured Associate Professor in 1994. Currently, she is a tenured Professor in the Lester and Sue Smith Breast Center at Baylor College of Medicine in Houston.

)

Baylor Coll. Med.
Houston, TX
USA

Q. Gao
Pharmaceutical Company Sanofi
Boston
USA

A.F Gazdar
University Texas SW Med. Ctr.
Dallas, TX
USA

A.J Giaccia (Biography
A.J Giaccia

Dr. Amato J. Giaccia obtained his Ph.D. in Pathology/Molecular Biology from the University of Pennsylvania in Philadelphia. He is a Professor of Radiation Oncology, Associate Chair for Research & Director of the Division of Radiation & Cancer Biology in the Department of Radiation Oncology. He also is the Director of Basic Science at the Stanford Cancer Institute and heads the Radiation Biology Program in Stanford’s Cancer Center. He co-authored the sixth & seventh editions of the textbook, “Radiation Biology for the Radiologist,” with Professor Eric Hall from Columbia. In addition, he is currently the “Jack, Lulu and Sam Willson Professor in Cancer Biology” in the Stanford University School of Medicine.

)

Stanford University
Stanford, CA
USA

A Giordano
Temple University
Philadelphia, PA
USA

S Grant
Virginia Commonwealth Univ. Med. Coll.
Richmond, VA
USA

D.H Gutmann
Washington Univ. Sch. Med
St. Louis, MO
USA

R Hawkins
Univ. Manchester
Manchester
UK

E Hiyama
Hiroshima University
Hiroshima
Japan

M.D Incalci (Biography
M.D Incalci

Maurizio D'Incalci obtained his Medical Degree cum Laude from the University of Milan (1978). Then he specialized in Pharmacology (1979) and in Oncology (1981). He worked in the Molecular Pharmacology Laboratory, NCI, Bethesda (1983-84). He is chief of the Cancer Chemotherapy Laboratory (since 1986) and of the Oncology Department (since 1996) at the Mario Negri Institute. He has been member of the board of several National and International organizations as EORTC, SENDO, SIC and he’s currently member of AIRC, MaNGO, Fondazione Mattioli, Fondazione Buzzi. He is author of more than 500 papers on cancer pharmacology and of several book chapters.

)

Istituto di Ricerche Farmacologiche Mario Negri
Milan
Italy

E.M Jaffee
Johns Hopkins Univ. Sch. Med.
Baltimore, MD
USA

B Kaina (Biography
B Kaina

Dr. Bernd Kaina obtained his Ph.D. in genetics in 1976 from the Universtity of Halle, Germany. He completed his postdoctoral training at the Institute of Genetics in Gatersleben and continued his studies on DNA repair at the Department of Molecular Biology in Leiden, Netherlands, at the German Cancer Research Center in Heidelberg and, as a Heisenberg fellow, at the Department of Genetics of the Nuclear Research Center in Karlsruhe, Germany. In 1993 he was appointed full professor for molecular toxicology at the Institute of Toxicology of the University of Mainz, where he is since 2003, director of the institute. He is author of more than 280 scientific publications and serves as editorial board member and reviewer for several scientific journals.

)

University of Mainz
Mainz
Germany

D Khayat (Biography
D Khayat

Dr. Khayat received his medical degree from the Pierre and Marie Curie University in Paris, where he completed his doctorate in tumor immunology and was Chief Clinical Assistant for the Department of Medical Oncology. He has taught at The University of Texas MD Anderson Cancer Center, Pierre and Marie Curie University in France, and Sino‐French Institute of Onco‐Hematology in China. He has been a visiting professor at the Mount Sinai School of Medicine.

)

Salpetriere Hosp.
Paris
France

D. Liao (Biography
D. Liao

Daiqing Liao, Ph.D., conducted his postdoctoral training at Yale University School of Medicine and is currently an Associate Professor at University of Florida College of Medicine and a member of UF Health Cancer Center. The research in his laboratory focuses on cancer epigenetics, metabolism, and signaling pathways as well as development of small molecule therapeutics targeting lysine acetyltransferases (HATs), deacetylases (HDACs), and metabolism for cancer therapy.

)

University of Florida College of Medicine
Gainesville, FL
USA

J Lunec
Univ. Newcastle upon Tyne
Newcastleupon Tyne
UK

J.D Marks
Univ. Calif. San Francisco General Hospital
San Francisco, CA
USA

H Mellstedt
Karolinska University Hospital Solna
Stockholm
Sweden

R Meredith (Biography
R Meredith

Ruby F. Meredith, MD, PhD is a Professor of Radiation Oncology at the University of Alabama at Birmingham. She is former Director of Research in that department, and a Senior Scientist at the University of Alabama at Birmingham Comprehensive Cancer Center. Her career includes basic science investigations and involvement in the conduct of scores of clinical trials, including 50 for targeted radionuclide therapy. Her activities are reflected in publications, memberships of scientific associations and she has served in numerous committees. Among her honors and awards, she has been selected for Best Doctor listings (greater than 10 years).

)

Univ. Alabama Med. Ctr.
Birmingham, AL
USA

J. Mulé (Biography
J. Mulé

Dr. Mulé is the Associate Center Director for Translational Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. Dr. Mulé, who was recently designated a “Master of Immunology” by the American Association for Cancer Research, is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in solid tumors. His clinical research group is involved in developing and validating genomic signatures of immunotherapy response, as well as vaccine strategies and other approaches to recognize and destroy tumors. The translational work in these areas has helped to develop new treatments for advanced cancer patients.

)

Moffitt Cancer Center
Tampa, FL
USA

K. Nath (Biography
K. Nath

Kavindra Nath is a Research Assistant Professor at the University of Pennsylvania, Perelman School of Medicine, Department of Radiology, Molecular Imaging Laboratory. He did his M.S. in Biochemistry, and Ph.D. in Magnetic Resonance Imaging and Spectroscopy (MRI/MRS). In Ph.D. His current research at University of Pennsylvania is utilizing multi-nuclear (1H, 31P, 13C) MRS and other techniques in vitro and in vivo in order to delineate the mode of action of various monocarboxylate transport (MCTs), mitochondrial pyruvate carrier (MPC) and electron transport chain (ETC) inhibitors, which distinguishes normal cells from malignant cells and potentiates the activities of various chemotherapeutic drugs, hyperthermia and radiation therapy in a variety of human cancers.

)

University of Pennsylvania
Philadelphia, Pennsylvania
USA

S Nishimura
University of Tsukuba
Tsukuba, Ibaraki
Japan

K Pantel (Biography
K Pantel

Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications. He has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and ERC Advanced Investigator Grant 2011. Moreover, Prof Pantel coordinates the European TRANSCAN group “CTC-SCAN”, the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies”.

)

Univ. Klinikum Hamburg
Hamburg
Germany

L.J Penn (Biography
L.J Penn

Dr. Penn (PhD) is a cancer research scientist at the Princess Margaret Cancer Centre. Her research focuses on the molecular basis of cancer and the development and application of novel anti-cancer therapeutics. She is also a Professor in the Medical Biophysics Department at the University of Toronto and Director of the University Health Network’s Office of the Research Trainee.

Dr. Penn is a scientific advisor on several national/international review panels and is on several journal editorial boards. She holds the Canada Research Chair in Molecular Oncology and is the recipient of an Honorary Doctorate Degree from Linkoping University in Sweden.

)

Princess Margaret Hosp. Ontario Canc. Inst.
Toronto, ON
Canada

M Pierotti
Pierotti
Milan
Italy

M.F Rajewsky
University of Essen Medical School
Essen
Germany

A Raz
Wayne State Univ. Sch. Med.
Detroit, MI
USA

I. J. Samudio (Biography
I. J. Samudio

Ismael obtained his Ph.D. in genetics from Texas A&M University in 2002, and received postdoctoral training in Immunotherapy at the BC Cancer Agency. Ismael joined The Centre for Drug Research and Development (CDRD) in 2015 and participated in the development of various immunotherapy platforms, including a novel targeting arm for CAR-T cells with potential for therapeutic efficacy against various solid tumors. Ismael is currently the Head of the Biologics Division at CDRD and has published over 70 peer reviewed articles and various book chapters on the use of small molecules, cellular therapeutics, and immunotherapy strategies for the treatment of cancer.

)

Universidad de Caldas
Manizales
Colombia

G.V Sherbet
University Newcastle Upon Tyne
Newcastle upon Tyne
UK

E.J Stanbridge
Univ Calif. Irvine
Irvine, CA
USA

C.F. Stewart
St. Jude Children's Research Hospital
Memphis, TN
USA

Y.-J. Surh
Seoul National University
Seoul
South Korea

C.H. Takimoto
Cancer Therapy and Research Center
San Antonio, TX
USA

E.L. Travis
Univ. Texas MD. Anderson Canc. Ctr.
Houston, TX
USA

C.L. Vecchia
Mario Negri Inst
Milan
Italy

S. Waxman
Mt. Sinai Sch. Med.
New York, NY
USA

P. Workman
Canc. Res. UK Ctr. Canc. Therapeut
Surrey
UK

J. Xiang
Saskatoon Cancer Center
Saskatoon
Canada

W. Zhang
Univ. Texas MD. Anderson Canc. Ctr.
Houston, TX
USA

A. Almasan
Cleveland Clin. Fdn. Lerner Res. Inst
Cleveland, OH
USA

M. Bar-Eli
Univ. Texas MD. Anderson Canc. Ctr
TX
USA

I.D. Bernstein
Fred Hutchinson Canc. Res. Ctr
Seattle, WA
USA

H. Bleiberg
Inst. Jules Bordet
Brussels
Belgium

R.H. Brakenhoff
Free University of Amsterdam
Amsterdam
The Netherlands

J. Cai (Biography
J. Cai

Dr. Cai is an ABR certified medical physicist and an Associate Professor of Radiation Oncology at Duke University Medical Center. Dr. Cai has published more than 60 peer-reviewed journal articles and over 190 conference abstracts. Dr. Cai’s research is mainly focused on developing and clinically implementing novel imaged guided radiation therapy techniques, with an emphasis on MRI. Dr. Cai regularly provides scientific reviews for peer-reviewed journals, conferences, and grant applications. His research has received federal, charitable, and industrial funding. Dr. Cai actively practice all aspects of clinical radiation physics, including treatment planning, quality control, brachytherapy, and stereotactic-body radiotherapy.

)

Duke University Medical Center
Durham, North Carolina
USA

W.K Cavenee (Biography
W.K Cavenee

Dr. Cavenee is Distinguished Professor of Medicine at the University of California at San Diego and Director, Strategic Alliances-CNS of Ludwig Cancer Research with global responsibilities. He is an elected member/fellow of the National Academy of Sciences, the National Academy of Medicine, the Leopoldina German Academy of Science, the AACR Academy, the International Union Against Cancer, the American Society for Clinical Investigation and the American Academy of Microbiology. He has published more than 370 scientific papers and received more than 100 honors, most notably the Charles S.

)

University of California at San Diego
La Jolla, CA
USA

L.W.K. Chung (Biography
L.W.K. Chung

Leland W. K. Chung is a Board of Governors Distinguished Cancer Research Chair and Director of the Uro-Oncology Research Program at Cedars-Sinai Medical Center and a Professor of Medicine, University of California at Los Angeles. His research focuses on the biology and therapy of lethal progression of cancer metastasis. He has published over 400 scientific papers, reviews, and invited book chapters and edited several scientific books. Dr. Chung earned his bachelor's degree from National Taiwan University, his master's degree in biochemistry from Oregon State University, and a doctorate in pharmacology from the University of Oregon Medical School. He then completed a postdoctoral fellowship in pharmacology and experimental therapeutics at Johns Hopkins University School of Medicine.

)

Samuel Oschin Comprehensive Cancer InstituteMonza
Los Angeles, CA
US

G Clayman
Univ. Texas MD. Anderson Canc. Ctr.
Houston, TX
USA

H Cortes-Funes
Med. Oncol. Serv. Hosp. University 12 de Octubre
Madrid
Spain

D.N. Danforth
National Cancer Institute, NIH
Bethesda, MD
USA

A. Deisseroth
Sidney Kimmel Cancer Center
San Diego, CA
USA

W.S. El-Deiry
University of Pennsylvania
Philadelphia, PA
USA

J.M. Ford
Stanford Univ. Sch. Med.
Stanford, NC
USA

D.K. Gaffney
University of Utah
Salt Lake City, UT
USA

S. Garattini
Mario Negri Inst. Pharmacol. Res.
Milan
Italy

K Geboes
University Hospital KUL
Leuven
Belgium

L Gianni
Istituto Nazionale dei Tumori
Milan
Italy

M.J Glennie
Southampton Gen. Hosp.
Hants
UK

E. Grassilli (Biography
E. Grassilli

Dr. Grassilli received her Ph.D. degree from the University of Modena, Italy, and pursued her post-doctoral research at Thomas Jefferson University, Philadelphia and European Institute of Oncology, Milan, studying the molecular mechanisms of apoptosis and their relevance in the response to chemotherapy. More recently, she co-founded Bionsil, a spin-off of the University of Milano-Bicocca, Italy, aimed at identifying and characterizing novel targets for molecular diagnosis and therapy of drug-resistant cancers. From 2014 she is Assistant Professor at the University of Milano-Bicocca where she continues her work on p65BTK, a novel Bruton’s Tyrosine isoform previously identified as a new target of therapy in colon cancers.

)

University of Milano-¬Bicocca
Monza
Itlay

H.-H Hann (Biography
H.-H Hann

Following Oncology Fellowship at Sidney Farber Cancer Institute, she joined Baruch Blumberg, the Nobel Laureate for discovery of HBV, at Fox Chase Cancer Center and worked on HBV, HCC, cancer enhancing effects of iron and anti-tumor effect of deferoxamine. Her new discovery included serum ferritin as the tumor and prognostic marker for neuroblastoma. Since 1988 she as the tenured Professor of Medicine and Director of Liver Disease Prevention Center at Thomas Jefferson University Hospital, has continued work on HBV as the Site Principal Investigator of 32 clinical trials evaluating anti-HBV agents (Lamivudine, Adefovir, Telbivudine, Entecavir, Tenofovir and TAF(Tenofovir alafenamide).

)

Thomas Jefferson University Hospital
Philadelphia, PA
USA

C.H Heldin (Biography
C.H Heldin

Since 1986, C.-H. Heldin is the Branch Director of the Ludwig Institute for Cancer Research in Uppsala, Sweden, and since 1992 is also the professor in Molecular Cell Biology at Uppsala University. He obtained a PhD degree in Medical and Physiological Chemistry in 1980 from the University of Uppsala, where he continued to work until 1985 using a position sponsored by the Swedish Cancer Society. C.-H. Heldin is the chair of the Boards of the Nobel Foundation, the Science for Life Laboratory, and the European Molecular Biology Organization. He has published more than 600 scientific papers.

)

Ludwig Institute for Cancer Research
Uppsala
Sweden

A.N Houghton
Memorial Sloan-Kettering Cancer Center
New York, NY
USA

E. Iorio (Biography
E. Iorio

Dr Egidio Iorio is a Researcher of Department of Cell Biology and Neurosciences at the Istituto Superiore di Sanità (Rome- Italy). Master Degree in Biological Sciences and Specialization in Clinical Pathology at University of Rome "La Sapienza". PhD in Biochemistry and Molecular Biology at University of Rome "Tor Vergata". The main research interests of Dr Iorio were focused on alterations in metabolism in relation to cell differentiation, tumor growth and cell death. He is actively involved in projects to develop original molecular imaging methods for the identifications of magnetic resonance spectroscopy biomarkers of tumour cell proliferation and response to therapy.

)

Istituto Superiore di Sanità
Roma
Italy

J Jassem
Medical University of Gdansk
Gdansk
Poland

R Kalluri
Harvard Univ. Sch. Med
Boston, MA
USA

Dmitri V. Krysko (Biography
Dmitri V. Krysko

Dmitri V. Krysko graduated from the Saratov State Medical University (Russia) in 1998 and then he moved to Belgium, where, in 2006, he obtained the Ph.D. degree from the Ghent University (Belgium). Dr. Krysko worked as a FWO Postdoctoral Scientist in the lab of Prof. Vandenabeele (VIB-Ghent University). From October 2016 Dr. Krysko has been appointed as Associate Professor at the Department of Basic Medical Sciences at Faculty of Medicine and Heath Sciences in Ghent University and a group leader of the CRIG (Cancer Research Institute Ghent). Dr. Krysko received several awards for his scientific work and serves as an Editorial Board Member of “Apoptosis” and “Mediators of Inflammation”. He published more than 60 articles in peer-reviewed international journals.

)

Ghent University
Ghent
Belgium

G Lopez-Berestein
Univ. Texas MD. Anderson Canc. Ctr.
Houston, TX
USA

H.T Lynch (Biography
H.T Lynch

Dr. Lynch obtained his M.D. degree from the University of Texas Medical Branch (Galveston). He is chairperson of Creighton University’s Department of Preventive Medicine and Public Health and Director of Creighton’s Hereditary Cancer Center. He has published more than 800 peer-reviewed publications. Dr. Lynch was instrumental in the identification of the hereditary breast-ovarian cancer syndrome, the Lynch syndrome, and the familial atypical multiple mole melanoma syndrome.

)

Creighton University Sch. Med.
Omaha, NE
USA

M.J Mckeage
University of Auckland
Auckland
New Zealand

W.M Mendenhall
Univ. Florida Coll. Med.
Gainesville, FL
USA

L Milas
Univ. Texas MD. Anderson Canc. Ctr.
Houston, TX
USA

B.C Nair
University of Texas MD Anderson Cancer Center
Houston
USA

B.J Nickoloff
Loyola University of Chicago Med. Ctr.
Maywood, IL
USA

V Notario
Georgetown Univ. Med. Ctr.
Washington, DC
USA

H.I Pass
NYU School of Medicine and NCI Cancer Center
New York, NY
USA

S Pestka
Robert Wood Johnson Med. Sch.
Piscataway, NJ
USA

G.C Prendergast (Biography
G.C Prendergast

Dr. Prendergast is an international leader in cancer research with special expertise in the preclinical discovery and development of molecular cancer therapeutics, with a recent emphasis on immunomodulators such as IDO inhibitors now in multiple Phase I/II clinical trials. He is currently President and CEO of the Lankenau Institute for Medical Research (LIMR), which employs a unique ‘acapreneurial’ organizational model to integrate biotech start-up companies with non-profit laboratory and clinical groups to speed translation of discoveries to clinic.

)

Thomas Jefferson University
Wynnewood, PA
USA

M.J Ratain
Univ. Chicago Canc. Res. Ctr.
Chicago, IL
USA

G.H Reaman
Childrens Natl. Med. Ctr.
Washington, DC
USA

J Schlom
National Cancer Institute, NIH
Bethesda, MD
USA

R. Soffietti
University of Turin
Turin
Italy

P.S. Steeg
National Cancer Institute NIH
Bethesda, MD
USA

Peter Storz (Biography
Peter Storz

Peter Storz, Ph.D. is an Associate Professor at the Mayo Clinic. He obtained his Ph.D. from the University of Stuttgart, Germany, and was a postdoctoral fellow and instructor at the Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, before he joined Mayo Clinic. Work in his laboratory focuses on inter- and intracellular signaling that leads to development and progression of pancreatic cancer. Specific interests are to understand the roles of acinar-to-ductal metaplasia and immune cell infiltration in these processes.

)

Mayo Clinic Jacksonville
Jacksonville, FL
US

E. Tahara
Hiroshima Cancer Seminar Foundation
Hiroshima
Japan

Z.Y Tang
Fudan University
Shanghai
China

M.A. VOOIJS (Biography
M.A. VOOIJS

Marc Vooijs is a division leader in the program for basic and translational cancer biology and a full professor and head of laboratory in the department of Radiotherapy (MAASTRO) at Maastricht University Medical Centre. He obtained his PhD at the University of Amsterdam developing tissue-specific KO models and did postdocs at Washington University St Louis and the Hubrecht Institute working on NOTCH signalling in cancer. Maastro lab focuses on the tumour microenvironment and treatment response in cancer and the lab uses normal stem cell models and advanced in vivo imaging to study tumour hypoxia and normal tissue repair. Web: www.maastrolab.nl

)

Maastricht University
Maastricht
Netherlands

H. Wallace (Biography
H. Wallace

Dr. Wallace is a Consultant in Pediatric Oncology at the Royal Hospital for Sick Children in Edinburgh and Honorary Professor at the University of Edinburgh. His main research interests are in fertility prediction and preservation for young cancer patients, Hodgkin lymphoma and mathematical modelling of biological systems. His website for more information on his research developments is:-
http://www.wallacekelsey.org.uk/

)

Royal Hospital for Sick Children
Edinburgh
UK

R.R. Weichselbaum
The University of Chicago
Chicago, IL
USA

Jie Wu (Biography
Jie Wu

Dr. Wu is a Professor in the Department of Pathology and the Peggy and Charles Stephenson Endowed Chair in Cancer Translational Research at the University of Oklahoma Health Sciences Center. Recently, Dr. Wu discovered recurrent JAK1 truncating mutations in endometrial cancer and frequent JAK2 deletion in non-small cell lung cancer (NSCLC) involving tumor immune evasion, and as a potential mechanism of resistance to immune checkpoint therapy. Dr. Wu has authored 80 original research papers plus additional review articles and book chapters. He has served on National Institutes of Health (NIH), NCI, DOD, and Department of Veterans Affairs (VA) grant review panels.

)

University of Oklahoma Health Sciences Center
Oklahoma, Ok
US

B. Yan
Shandong University
Jinan
China


Advertisement

Related Journals





Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science